• Otsuka Pharmaceutical's QuickNavi-Flu, a rapid diagnostic test kit for the influenza virus, has the leading market share in Japan among products in this category. In order to strengthen the provision of information to medical institutions on how to use the product, easy-to-understand images can be viewed using free application software.
• Every year in Japan, 14 million patients receive an examination and diagnostic test for influenza at a medical institution.^*1 Amidst a steady increase in the number of people examined for influenza in Japan, the rapid diagnostic kit QuickNavi-Flu has earned a high reputation in medical settings.
• Otsuka's medical diagnostics business has developed more than 10 measurement kits for outside-of-body (extracorporeal) diagnosis in fields such as infectious diseases and oncology. A co-promotion organization handles sales of the line-up of diagnostic kits and other medical devices that contribute to rapid and appropriate diagnosis and treatment, as well as to disease prevention.

Otsuka Pharmaceutical Co. Ltd., which markets the in vitro influenza diagnostic test QuickNavi^™-Flu, has released to medical institutions a related new software application (app) "Know With AR! Influenza" provided as a new tool for diagnostic-related information. This app utilizes AR technology to enable viewing and printouts of three-dimensional illustrations and images taken by a camera in a smartphone or tablet.^*2 This technology-based advance in the provision of information on the testing methodology and on the disease itself is a first among Japanese domestic diagnostic test manufacturers.

• *1 The number of patients varies based on the intensity of the flu season.
• *2 AR stands for augmented reality. The AR app can be downloaded to a smartphone or tablet. Three-dimensional images can then be viewed on the screen of the phone or tablet screen using the camera function.